NCT02311621: Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 |
|
|
| Active, not recruiting | 1 | 65 | US | Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells), Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells), Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells) | Seattle Children's Hospital, The Evan Foundation, Ben Towne Center for Childhood Cancer Research | Neuroblastoma, Ganglioneuroblastoma | 11/23 | 11/38 | | |
